Expected outcomes and patients’ selection before chemoembolization—“Six-and-Twelve or Pre-TACE-Predict” scores may help clinicians: Real-life French cohorts results

Table 5 Kaplan-Meier survival analysis according to scores and other systems in cohort 2 (n = 137)

Scoring/Staging systems	OS (95%CI), mo	P value (log-rank)	Sidak1	Hazard ratio (95%CI)	P value
Pre-TACE-Predict		0.0032
Category 1 (n = 32)	26 (21-44)		Ref	Ref
Category 2 (n = 35)	30 (17-50)		0.8786	0.83 (0.46-1.52)	0.5463
Category 3 (n = 47)	16 (11-20)		0.2611	1.56 (0.92-2.65)	2.6614
Category 4 (n = 23)	12 (5-15)		0.0418	2.27 (1.24-4.14)	0.0079
Post-TACE-Predict		0.0022
Category 1 (n = 36)	36 (23-44)		Ref	Ref
Category 2 (n = 38)	21 (12-30)		0.4851	1.47 (0.83-2.61)	0.1843
Category 3 (n = 48)	16 (12-24)		0.0699	1.89 (1.10-3.23)	0.0203
Category 4 (n = 15)	9 (5-15)		0.0022	3.68 (1.79-7.55)	0.0004
“6 and 12” score		0.8633
Sum ≤ 6 (n = 51)	26 (16-36)		Ref	Ref
Sum 6-12 (n = 73)	18 (15-23)		0.8328	1.12 (0.74-1.70)	0.5913
Sum > 12 (n = 13)	24 (3-48)		0.8867	1.09 (0.54-2.18)	0.8159
BCLC staging		0.0234
B (n = 58)	29 (18-39)		-	Ref
C (n = 79)	16 (13-21)		-	1.58 (1.06-2.36)	0.0253
NIACE score		< 0.0001
≤ 1 (n = 41)	29 (21-43)		Ref	Ref
1.5-3 (n = 72)	22 (16-30)		0.5463	1.38 (0.86-2.19)	0.1782
> 3 (n = 24)	9 (5-12)		< 0.0001	3.69 (2.09-6.51)	< 0.0001
Child-Pugh class		< 0.0001
A (n = 126)	23 (18-29)		-	Ref
B (n = 11)	9 (6-11)		-	4.74 (2.34-9.59)	< 0.0001
ALBI grade		< 0.0001
Grade 1 (n = 51)	32 (25-44)		Ref	Ref
Grade 2 (n = 77)	17 (12-21)		0.0074	1.93 (1.26-2.97)	0.0026
Grade 3 (n = 9)	9 (1-16)		< 0.0001	6.82 (3.14-14.83)	< 0.0001

¹Sidak test for multiple comparisons. OS: Overall survival; CI: Confidence interval; “6 and 12”: “Six-and-Twelve”; Ref: Reference; BCLC: Barcelona Clinic Liver Cancer; NIACE: Number of tumor(s), Infiltrative hepatocellular carcinoma, Alpha-fetoprotein, Child-Pugh class, Eastern Cooperative Oncology Group Performance Status; ALBI: Albumin-Bilirubin.